Advantages of AlloMSCs
Bioceltix’s MSC-based veterinary products use safe allografts for batch production, avoiding patient-specific material collection.
bioceltix.comCrawled Nov 20, 2026
Bioceltix’s MSC-based veterinary products use safe allografts for batch production, avoiding patient-specific material collection.
Bioceltix’s technology produces veterinary MSC-based drugs using allogenic grafts, enabling serial production without repeated patient sampling.
Bioceltix develops veterinary biological drugs prioritizing patient safety and therapy effectiveness, targeting degenerative joint disease and skin inflammation in dogs.
The page explains how biopharmaceuticals are produced in bioreactors, contrasts them with chemically synthesized drugs, and outlines the full process for creating allogeneic MSC-based products.
Bioceltix develops MSC-based medicines for dogs, horses, and cats in Poland, leveraging stem cells’ anti-inflammatory and pain-relief properties.
Bioceltix’s EU-funded project produces allogenic mesenchymal stem cells for veterinary advanced therapy clinical trials in dogs.
Dr Ewa Karuga-Kuźniewska coordinates clinical research at Bioceltix, overseeing stem cell-based biological drug trials.
Pracelo received SME status from the European Medicines Agency in 2017.
Bioceltix focuses on veterinary biopharmaceuticals for animal ailments.
Bioceltix develops stem cell-based veterinary pharmaceuticals with scientists at the Wrocław Research Centre EIT+.
Pracelo held a pre-submission meeting with the European Medicines Agency in 2017 to discuss regulatory issues for a veterinary product based on allogenic mesenchymal stem cells for degenerative changes in dogs.
Bioceltix SA is a Polish biotechnology company specializing in veterinary biologics, listed on the Warsaw Stock Exchange.